Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136415 | 0.88 | DHFR (0.46) | CA2CA12CA9CA1PTGS2 | |
| SCHEMBL5994743 | 0.82 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL3248192 | 0.80 | MAOA (0.48) | CA2CA9CA1PTGS2 | |
| SCHEMBL5134484 | 0.76 | PTGS2 (0.48) | CA2CA1PTGS2ALDH1A1EGFR | |
| SCHEMBL7714429 | 0.75 | POLB (0.81) | CA2CA12CA9CA1POLB | |
| SCHEMBL7968587 | 0.68 | PTGS2 (0.45) | CA2CA12CA9CA1PTGS2 | |
| SCHEMBL2644701 | 0.67 | KDM1A (0.34) | SMN1; SMN2TDP1ALDH1A1IDO1 | |
| SCHEMBL15625449 | 0.64 | PTGS2 (0.63) | CA2CA12CA9CA1POLB | |
| SCHEMBL12187037 | 0.63 | CA1 (0.66) | CA2CA9CA1POLBPTGS2 | |
| Sulfacetamide SCHEMBL40863 | 0.63 | SMN1; SMN2 (1.00) | CA2CA12CA9CA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-6815460-B2 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | CA2 920/4885CA12 3332/4885CA9 1174/4885 |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PTGS2, PTGES2, PTGES | CA2 1013/4885CA12 3504/4885CA9 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.